Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019760 · ClinicalTrials.gov registry record · Phase 2
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
A Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019760: Completed Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
NCT00019760 is a Phase 2 study that has completed, run by National Institutes of Health Clinical Center (CC). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019760, a Phase 2 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of melphalan given as an isolated hepatic perfusion followed by chemotherapy infused into the liver in patients who have unresectable colorectal cancer that is metastatic to the liver.
Interventions
- DRUG leucovorin calcium
- DRUG melphalan
- DRUG floxuridine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-04 |
| Est. Completion | 2002-03 |
| Phase | Phase 2 |
What the finished NCT00019760 record still lists
NCT00019760 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which leucovorin calcium is the first listed.
NCT00019760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019760 about?
NCT00019760 is a clinical study titled "Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of melphalan given as an isolated hepa...
What is the current status of trial NCT00019760?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-04. Estimated completion is 2002-03.
What interventions are being tested in trial NCT00019760?
The interventions under investigation include: leucovorin calcium (DRUG), melphalan (DRUG), floxuridine (DRUG).
Who is sponsoring clinical trial NCT00019760?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia